All In Biotech

Drug Trial Radar · NCT06505551

Phase 1/2 Study of Autologous SCG142 TCR T Cells in Patients With HPV16/52-positive Carcinoma

A Phase 1/2 Open Label, Single Arm, Multicenter Study to Evaluate the Safety and Preliminary Eficacy of Autologous SCG142 T Cell Receptor (TCR) T Cells in Patients With Advanced or Metastatic HPV16- or HPV52-positive Carcinomas

Last checked: Nov 19, 2026Latest source record: Jul 17, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

Not yet recruiting

Status

Not yet recruiting

Enrollment

66

Planned (sponsor's estimate)

Start

Oct 2024

Primary completion

Dec 2026

Study completion Dec 2028

Sponsor

Lead sponsor
SCG Cell Therapy Pte. Ltd.Industry
Sponsor type
Industry
First posted
Jul 17, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a phase 1/2, open-label, single arm, multicenter study in patients with advanced or metastatic HPV16- or HPV52-positive carcinomas who have progressed after at least one line of systemic therapy, including but not limited to combination chemotherapy and/or combination chemo-immunotherapy

Conditions

  • HPV-Related Squamous Cell Carcinoma
  • HPV-Related Cervical Squamous Cell Carcinoma
  • HPV-Related Vulvar Squamous Cell Carcinoma
  • HPV-Related Penile Squamous Cell Carcinoma
  • HPV-Related Vaginal Squamous Cell Carcinoma
  • HPV-Related Anal Squamous Cell Carcinoma
  • HPV-Related Head and Neck Cancer

Interventions

  • SCG142Biological

    Autologous SCG142 cells infused on Day 0 after completion of lymphedepletion chemotherapy

  • CyclophosphamideDrug

    for 3 consecutive days

  • FludarabineDrug

    for 3 consecutive days

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Incidence of Treatment-Emergent Adverse Events (Phase 1)Time frame: 2 years
  2. Objective response rate (ORR) (Phase 2)Time frame: 2 years

Locations

No sites are listed on the registry yet.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.